These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27147083)

  • 1. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
    Pajtler KW; Tippelt S; Siegler N; Reichling S; Zimmermann M; Mikasch R; Bode U; Gnekow A; Pietsch T; Benesch M; Rutkowski S; Fleischhack G
    J Neurooncol; 2016 Jul; 128(3):463-71. PubMed ID: 27147083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.
    Fleischhack G; Reif S; Hasan C; Jaehde U; Hettmer S; Bode U
    Br J Cancer; 2001 Jun; 84(11):1453-9. PubMed ID: 11384092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.
    Chamberlain MC
    Pediatr Neurol; 2001 Feb; 24(2):117-21. PubMed ID: 11275460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
    Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
    J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
    Needle MN; Molloy PT; Geyer JR; Herman-Liu A; Belasco JB; Goldwein JW; Sutton L; Phillips PC
    Med Pediatr Oncol; 1997 Jul; 29(1):28-32. PubMed ID: 9142202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
    Watanabe K; Kanaya H; Fujiyama Y; Kim P
    Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of recurrent medulloblastoma to low-dose oral etoposide.
    Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
    J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.
    Busca A; Miniero R; Besenzon L; Cordero di Montezemolo L; Cenni M; Fagioli F; Sandri A; Vassallo E; Ricardi U; Madon E
    Childs Nerv Syst; 1997; 13(11-12):572-7. PubMed ID: 9454971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
    Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
    Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral etoposide for recurrent/progressive sarcomas of childhood.
    Kebudi R; Görgün O; Ayan I
    Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
    Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
    JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
    Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Tominaga T
    No Shinkei Geka; 2010 Nov; 38(11):997-1005. PubMed ID: 21081811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy for recurrent spinal cord ependymona.
    Chamberlain MC
    Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.
    Fiorillo A; Maggi G; Greco N; Migliorati R; D'Amico A; De Caro MD; Sabbatino MS; Buffardi F
    J Neurooncol; 2004 Jan; 66(1-2):179-85. PubMed ID: 15015784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Korones DN; Smith A; Foreman N; Bouffet E
    Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
    Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
    J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
    Jakacki RI; Foley MA; Horan J; Wang J; Kieran MW; Bowers DC; Bouffet E; Zacharoulis S; Gill SC
    J Neurooncol; 2016 Aug; 129(1):131-8. PubMed ID: 27287856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.